Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Company Growth (employees)
Milton, GB
Size (employees)
432 (est)
Oxford Immunotec was founded in 2001 and is headquartered in Milton, GB

Key People at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

Richard M. Altieri

Richard M. Altieri


Oxford Immunotec Office Locations

Oxford Immunotec has offices in Milton, Kohoku Ward, Marlborough, Shanghai
Milton, GB
Shanghai, CN
Marlborough, US
Kohoku Ward, JP

Oxford Immunotec Metrics

Oxford Immunotec Summary

Market capitalization

$349 m

Closing share price

Oxford Immunotec's current market capitalization is $349 m.

Oxford Immunotec Financials

Oxford Immunotec's revenue is £25.5 m in FY, 2013 which is a 30.3% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


£25.5 m£36.6 m£46.4 m

Revenue growth, %


Cost of sales

£12.2 m£17.8 m£21.8 m

Gross profit

£13.3 m£18.9 m£24.6 m

Gross profit Margin, %


Operating expense total

£17.7 m£34.9 m£42.4 m

Oxford Immunotec Market Value History

Oxford Immunotec Online Presence

Oxford Immunotec Company Life

You may also be interested in